Stem Cell Therapy
Cell dose is a key limitation for stem cell transplant success and for its use as a curative therapy. GIRUS' Directed Cell Trafficking Technology™ (DCT) overcomes this key limitation.
DCT:
- Significantly increases the number of injected stem cells that infiltrate the bone
marrow, improving chances of transplant success - Is non-invasive and independent of other technologies
- Is enabling:
- Is the only technology that allows use of fewer bone marrow and mobilized
stem cells - Is being developed to facilitate routine use of cord blood stem cells in
transplants for adults
- Is the only technology that allows use of fewer bone marrow and mobilized
- Can reduce necessity for:
- repeated apheresis procedures
- blood transfusions
- extended antibiotic treatments and hospitalization
- patient discomfort
- Can significantly reduce costs